ArticleeLife2020
Squalene emulsion-based vaccine adjuvants stimulate CD8 T cell, but not antibody responses, through a RIPK3-dependent pathway.
Article in eLife, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 53 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
53 citing papers in PubMed, 83 citations in OpenAlex.
- mRNA vaccines engage unconventional pathways in CD8Nature · 2026Article
- Cooperative supramolecular integration of QS-21 into polymeric micelles as a tunable nanoadjuvant platform for subunit vaccines.RSC advances · 2026Article
- IL-1 delineates squalene-based adjuvant efficacy and reactogenicity in a cell-type-specific manner.NPJ vaccines · 2026Article
- Assessment of Mycobacterium tuberculosis dodecin scaffold as a multimerization platform on the immunogenicity of HPV L2 antigens.Scientific reports · 2026Article
- Adjuvants enhance protective antibodies against seasonal influenza viruses following a single vaccination of Fluzone.Virology · 2026Article
- Subunit vaccination using Atomic Layering Thermostable Antigen and Adjuvant (ALTAFrontiers in immunology · 2026Article
- Immunogenicity and vaccine efficacy ofVirulence · 2025Article
- Comparison of Adjuvant Potency of Alum, AddaVax, and ISA 71 VG on the Seasonal Split Influenza Vaccine in Mice.Microorganisms · 2025Article
- Galectin-4 potentiates CD8+ T cell immunity by enhancing MHC-I expression on dendritic cells.Molecular therapy : the journal of the American Society of Gene Therapy · 2025Article
- Article
- MF59-like adjuvant containing yeast-derived squalene enhances the humoral immune response to cell-derived influenza vaccine.Archives of virology · 2025Article
- Cellular immune signatures and differences of four porcine circovirus type 2 vaccines to heterologous PCV2d infection.NPJ vaccines · 2025Article
- Emulsion adjuvant-induced uric acid release modulates optimal immunogenicity by targeting dendritic cells and B cells.NPJ vaccines · 2025Article
- Modulation of lipid nanoparticle-formulated plasmid DNA drives innate immune activation promoting adaptive immunity.Cell reports. Medicine · 2025Article
- Linking vaccine adjuvant mechanisms of action to function.Science immunology · 2025Review
- How Advanced are Self-Assembled Nanomaterials for Targeted Drug Delivery? A Comprehensive Review of the Literature.International journal of nanomedicine · 2025Review
- The role of cell death pathways in respiratory viral infection and vaccination: two sides of the same coin.Frontiers in immunology · 2025Review
- Rationally designed Mycoplasma gallisepticum vaccine using a recombinant subunit approach.NPJ vaccines · 2024Article
- Vaccine adjuvants for infectious disease in the clinic.Bioengineering & translational medicine · 2024Review
- Differential Regulation of DC Function, Adaptive Immunity, and MyD88 Dependence by Two Squalene Emulsion-Based Vaccine AdjuvantsVaccines · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors at 4 institutions in 2 countries.
Funding
Abstract
The squalene-based oil-in-water emulsion (SE) vaccine adjuvant MF59 has been administered to more than 100 million people in more than 30 countries, in both seasonal and pandemic influenza vaccines. Despite its wide use and efficacy, its mechanisms of action remain unclear. In this study we demonstrate that immunization of mice with MF59 or its mimetic AddaVax (AV) plus soluble antigen results in robust antigen-specific antibody and CD8 T cell responses in lymph nodes and non-lymphoid tissues. Immunization triggered rapid RIPK3-kinase dependent necroptosis in the lymph node which peaked at 6 hr, followed by a sequential wave of apoptosis. Immunization with alum plus antigen did not induce RIPK3-dependent signaling. RIPK3-dependent signaling induced by MF59 or AV was essential for cross-presentation of antigen to CD8 T cells by Batf3-dependent CD8
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.